Guardant Health Stock News

Brokerages predict that Guardant Health, Inc. (NASDAQ:GH) will report earnings of ($1.06) per share for the current quarter, Zacks reports. Six analysts have made estimates for Guardant Healths earnings. The lowest EPS estimate is ($1.28) and the highest is ($0.80). Guardant Health reported earnings per share of ($0.94) during the same quarter last year, which []

Equities analysts predict that Guardant Health, Inc. (NASDAQ:GH) will announce sales of $98.95 million for the current quarter, Zacks reports. Six analysts have provided estimates for Guardant Health’s earnings, with the highest sales estimate coming in at $102.26 million and the lowest estimate coming in at $97.44 million. Guardant Health posted sales of $78.32 million […]

New investors include US life science investors HealthQuest Capital, Casdin Capital, and American Cancer Society BrightEdge, and Asia-based global healthcare investors Tybourne Capital Management and NSG Ventures Following the most recent strategic investment of $26 million from Guardant Health, the company has now secured more than $135 million in total ahead of its planned KOSDAQ IPO next [] The post Medical AI Provider Lunit Raises $61Million In Funding Round Led By Major Global Healthcare Investors appeared first on AiThority .

- New investors include US life science investors HealthQuest Capital, Casdin Capital, and American Cancer Society BrightEdge, and Asia -based global healthcare investors Tybourne Capital Management and NSG Ventures - Following the most recent strategic investment of $26 million from Guardant Health, the company has now secured more than $135 million in total ahead of its planned KOSDAQ IPO next year SEOUL, South Korea , Nov. 25, 2021 /PRNewswire/ -- Lunit, a leading medical AI provider, today announced it has raised $61 million in its Pre-IPO fundraising round ahead of the company''s planned public offering on the South Korean stock market (KOSDAQ) early next year. A number of new investors have joined the round including leading US healthcare investors HealthQuest Capital, Casdin Capital, and American Cancer Society BrightEdge, as well as Asia -based global healthcare investors Tybourne Capital Management, and NSG Ventures. HealthQuest Capital invested $20 million of the total funding amount.

Related Stocks: GH ,

Guardant Health, Inc. (NASDAQ:GH) CEO Helmy Eltoukhy purchased 54,500 shares of the firms stock in a transaction on Tuesday, November 23rd. The shares were purchased at an average price of $94.36 per share, with a total value of $5,142,620.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is []

Shares of Guardant Health, Inc. (NASDAQ:GH) have been given a consensus rating of Buy by the fifteen ratings firms that are covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and ten have given a buy recommendation to the company. The average 1 year price target among []

Key Companies Covered in the Liquid Biopsy Market Research Report Are Qiagen, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Illumina, Inc., Inivata Limited, Agena Bioscience, Inc., Thermo Fisher Scientific, Guardant Health, Inc., and other key market players. Key Companies Covered in the Liquid Biopsy Market Research Report Are Qiagen, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Illumina, Inc., Inivata Limited, Agena Bioscience, Inc., Thermo Fisher Scientific, Guardant Health, Inc., and other key market players.

Prudential Financial Inc. grew its stake in Guardant Health, Inc. (NASDAQ:GH) by 7.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 43,273 shares of the companys stock after acquiring an additional 3,174 shares during the quarter. Prudential Financial Inc.s holdings []

Guardant Health Inc (NASDAQ: GH) reported Q3 sales of $94.8 million, +27% Y/Y, beating the Wall Street estimate of $92.64 million. Guardant's Q3 precision oncology revenues grew 31% to $79.3 million

Guardant Health (GH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

The stock price of Guardant Health, a healthcare company that offers non-invasive cancer diagnosis tests, has seen an 18% fall over the last twenty-one trading days. This can be attributed to its plan

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2021 after marke

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has initiated the Observation of ResiduAl Cancer with Liquid biopsy Evaluation (ORACLE)